| Year |
Citation |
Score |
| 2024 |
Ye Z, Xu S, Shi Y, Cheng X, Zhang Y, Roy S, Namjoshi S, Longo MA, Link TM, Schlacher K, Peng G, Yu D, Wang B, Tainer JA, Ahmed Z. GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancer. Nature Communications. 15: 2132. PMID 38459011 DOI: 10.1038/s41467-024-46283-y |
0.32 |
|
| 2024 |
Liu C, Zhou C, Xia W, Zhou Y, Qiu Y, Weng J, Zhou Q, Chen W, Wang YN, Lee HH, Wang SC, Kuang M, Yu D, Ren N, Hung MC. Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma. Nature Communications. 15: 1009. PMID 38307859 DOI: 10.1038/s41467-024-45215-0 |
0.486 |
|
| 2023 |
Akkoc Mustafayev FN, Liu DD, Gutierrez AM, Lewis JE, Ibrahim NK, Valero V, Booser DJ, Litton JK, Koenig K, Yu D, Sneige N, Arun BK. Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention. European Journal of Breast Health. 19: 267-273. PMID 37795002 DOI: 10.4274/ejbh.galenos.2023.2023-7-3 |
0.385 |
|
| 2023 |
Wang YN, Lee HH, Jiang Z, Chan LC, Hortobagyi GN, Yu D, Hung MC. Ribonuclease 1 Enhances Antitumor Immunity against Breast Cancer by Boosting T cell Activation. International Journal of Biological Sciences. 19: 2957-2973. PMID 37416781 DOI: 10.7150/ijbs.84592 |
0.565 |
|
| 2023 |
Zhang Y, Zhao Z, Huang LA, Liu Y, Yao J, Sun C, Li Y, Zhang Z, Ye Y, Yuan F, Nguyen TK, Garlapati NR, Wu A, Egranov SD, Caudle AS, ... ... Yu D, et al. Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. Cell Metabolism. PMID 37329887 DOI: 10.1016/j.cmet.2023.05.009 |
0.38 |
|
| 2023 |
Sun C, Ye Y, Tan Z, Liu Y, Li Y, Hu W, Liang K, Egranov SD, Huang LA, Zhang Z, Zhang Y, Yao J, Nguyen TK, Zhao Z, Wu A, ... ... Yu D, et al. Tumor-associated nonmyelinating Schwann cell-expressed promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Science Advances. 9: eadd6995. PMID 36724291 DOI: 10.1126/sciadv.add6995 |
0.494 |
|
| 2022 |
Zhang Y, Sun C, Li Y, Qin J, Amancherla K, Jing Y, Hu Q, Liang K, Zhang Z, Ye Y, Huang LA, Nguyen TK, Egranov SD, Zhao Z, Wu A, ... ... Yu D, et al. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Science Translational Medicine. 14: eabo1981. PMID 36322628 DOI: 10.1126/scitranslmed.abo1981 |
0.409 |
|
| 2022 |
Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Jiang Z, Liu C, Li CF, Nie L, ... ... Yu D, et al. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nature Cancer. PMID 36253486 DOI: 10.1038/s43018-022-00438-2 |
0.552 |
|
| 2022 |
Zhang L, Qu J, Qi Y, Duan Y, Huang YW, Zhou Z, Li P, Yao J, Huang B, Zhang S, Yu D. EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin β1-FAK activation. Nature Communications. 13: 2543. PMID 35538070 DOI: 10.1038/s41467-022-30105-0 |
0.417 |
|
| 2022 |
Zhao X, Wei Y, Chu YY, Li Y, Hsu JM, Jiang Z, Liu C, Hsu JL, Chang WC, Yang R, Chan LC, Qu J, Zhang S, Ying H, Yu D, et al. Phosphorylation and stabilization of PD-L1 by CK2 suppresses dendritic cell function. Cancer Research. PMID 35385574 DOI: 10.1158/0008-5472.CAN-21-2300 |
0.386 |
|
| 2022 |
Cha JH, Chan LC, Wang YN, Chu YY, Wang CH, Lee HH, Xia W, Shyu WC, Liu SP, Yao J, Chang CW, Cheng FR, Liu J, Lim SO, Hsu JL, ... ... Yu D, et al. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. The Journal of Biological Chemistry. 101817. PMID 35278434 DOI: 10.1016/j.jbc.2022.101817 |
0.552 |
|
| 2022 |
Wang YN, Lee HH, Wei Y, Chu YY, Xia W, Wang M, Yu D, Hung MC. An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response. Star Protocols. 3: 101198. PMID 35243381 DOI: 10.1016/j.xpro.2022.101198 |
0.35 |
|
| 2021 |
Qiu Y, Yang Y, Yang R, Liu C, Hsu JM, Jiang Z, Sun L, Wei Y, Li CW, Yu D, Zhang J, Hung MC. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. Oncogene. PMID 34172932 DOI: 10.1038/s41388-021-01896-1 |
0.418 |
|
| 2021 |
Wang J, Zhang Y, Xiao Y, Yuan X, Li P, Wang X, Duan Y, Seewaldt VL, Yu D. Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer. American Journal of Cancer Research. 11: 2005-2024. PMID 34094666 |
0.454 |
|
| 2021 |
Lee HH, Wang YN, Yang WH, Xia W, Wei Y, Chan LC, Wang YH, Jiang Z, Xu S, Yao J, Qiu Y, Hsu YH, Hwang WL, Yan M, Cha JH, ... ... Yu D, et al. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nature Communications. 12: 2788. PMID 33986289 DOI: 10.1038/s41467-021-23075-2 |
0.61 |
|
| 2021 |
Jiang Z, Lim SO, Yan M, Hsu JL, Yao J, Wei Y, Chang SS, Yamaguchi H, Lee HH, Ke B, Hsu JM, Chan LC, Hortobagyi GN, Yang L, Lin C, ... Yu D, et al. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. The Journal of Clinical Investigation. 131. PMID 33855973 DOI: 10.1172/JCI139434 |
0.373 |
|
| 2021 |
Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, Yan M, Chang WC, Hsu JM, Cha JH, Hsu JL, Chou CW, Sun X, Deng Y, Chou CK, ... Yu D, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nature Communications. 12: 832. PMID 33547304 DOI: 10.1038/s41467-021-21099-2 |
0.627 |
|
| 2021 |
Gao Y, Chen MK, Chu YY, Yang L, Yu D, Liu Y, Hung MC. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. American Journal of Cancer Research. 11: 236-250. PMID 33520371 |
0.519 |
|
| 2021 |
Fukumura K, Malgulwar PB, Fischer GM, Hu X, Mao X, Song X, Hernandez SD, Zhang XH, Zhang J, Parra ER, Yu D, Debeb BG, Davies MA, Huse JT. Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathologica. PMID 33394124 DOI: 10.1007/s00401-020-02256-1 |
0.301 |
|
| 2020 |
Wang YN, Lee HH, Hsu JL, Yu D, Hung MC. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. Journal of Biomedical Science. 27: 77. PMID 32620165 DOI: 10.1186/S12929-020-00670-X |
0.435 |
|
| 2020 |
Zhang L, Yao J, Wei Y, Zhou Z, Li P, Qu J, Badu-Nkansah A, Yuan X, Huang YW, Fukumura K, Mao X, Chang WC, Saunus J, Lakhani S, Huse JT, ... ... Yu D, et al. Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. Science Translational Medicine. 12. PMID 32461334 DOI: 10.1126/Scitranslmed.Aaz5387 |
0.469 |
|
| 2020 |
Chen M, Xia W, Dong Q, Du Y, Wang H, Tapia C, Wei Y, Han Y, Chu Y, Yam C, Gao Y, Wang Y, Meric-Bernstam F, Liu J, Wang S, ... Yu D, et al. Abstract 5682: Synergism of PARP inhibitor and MET inhibitor in multiple cancer types with intrinsic and acquired PARP inhibitor resistances Cancer Research. 80: 5682-5682. DOI: 10.1158/1538-7445.Am2020-5682 |
0.547 |
|
| 2020 |
Yuzhalin AE, Yu D, Muschel RJ. Abstract 3947: Mass-spectrometry analysis of metastatic matrisome from MC38 experimental liver metastasis Cancer Research. 80: 3947-3947. DOI: 10.1158/1538-7445.Am2020-3947 |
0.341 |
|
| 2020 |
Huang Y, Zhang L, Qu J, Zhou Z, Yu D. Abstract 3844: EZH2 engages TGF-β signaling to promote breast cancer bone metastasis Tumor Biology. DOI: 10.1158/1538-7445.Am2020-3844 |
0.416 |
|
| 2019 |
Zhang C, Yu D. Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain? Cell & Bioscience. 9: 82. PMID 31624532 DOI: 10.1186/S13578-019-0349-0 |
0.355 |
|
| 2019 |
Acharya S, Yao J, Li P, Zhang C, Lowery FJ, Zhang Q, Guo H, Qu J, Yang F, Wistuba II, Piwnica-Worms H, Sahin AA, Yu D. Sphingosine-kinase-1 signaling promotes metastasis of triple-negative breast cancer. Cancer Research. PMID 31239273 DOI: 10.1158/0008-5472.Can-18-3803 |
0.586 |
|
| 2019 |
Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, Egranov SD, Zhang Y, Xia W, Gong J, Pan Y, Chatterjee SS, Yao J, Evans KW, Nguyen TK, ... ... Yu D, et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nature Immunology. PMID 31160797 DOI: 10.1038/S41590-019-0400-7 |
0.603 |
|
| 2019 |
Zijlstra A, Von Lersner A, Yu D, Borrello L, Oudin M, Kang Y, Sahai E, Fingleton B, Stein U, Cox TR, Price JT, Kato Y, Welm AL, Aguirre-Ghiso JA. The importance of developing therapies targeting the biological spectrum of metastatic disease. Clinical & Experimental Metastasis. PMID 31102066 DOI: 10.1007/S10585-019-09972-3 |
0.303 |
|
| 2019 |
Qu J, Zhang L, Zhou Z, Yu D. Abstract 2739: EZH2 promotes breast cancer bone metastasis Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2739 |
0.454 |
|
| 2018 |
Zhou Z, Li M, Zhang L, Zhao H, Şahin Ö, Chen J, Zhao JJ, Songyang Z, Yu D. Oncogenic kinase-induced PKM2 tyrosine 105 phosphorylation converts non-oncogenic PKM2 to a tumor promoter and induces cancer stem-like cells. Cancer Research. PMID 29440169 DOI: 10.1158/0008-5472.Can-17-2726 |
0.52 |
|
| 2018 |
Li H, Xiao Y, Yuan X, Kuo W, Li P, Yu D. Abstract 59: 14-3-3zeta overexpressing breast cancer cells promote fibroblast senescence and CAF-like phenotype Cancer Research. 78: 59-59. DOI: 10.1158/1538-7445.Am2018-59 |
0.536 |
|
| 2018 |
Yuan X, Xiao Y, Liu X, Kuo W, Li H, Li P, Yagita H, Yu D. Abstract 4565: Effective inhibition of metastasis in triple-negative breast cancer (TNBC) mouse model by combining immunogenic chemotherapy and immune checkpoint blockade Cancer Research. 78: 4565-4565. DOI: 10.1158/1538-7445.Am2018-4565 |
0.532 |
|
| 2017 |
Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, ... ... Yu D, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. The Journal of Clinical Investigation. PMID 29130936 DOI: 10.1172/Jci91553 |
0.63 |
|
| 2017 |
Yang J, Joshi S, Wang Q, Li P, Wang H, Xiong Y, Xiao Y, Wang J, Parker-Thornburg J, Behringer RR, Yu D. 14-3-3ζ loss leads to neonatal lethality by microRNA-126 downregulation-mediated developmental defects in lung vasculature. Cell & Bioscience. 7: 58. PMID 29118970 DOI: 10.1186/S13578-017-0186-Y |
0.577 |
|
| 2017 |
Wang X, Yao J, Wang J, Zhang Q, Brady SW, Arun B, Seewaldt V, Yu D. Targeting Aberrant p70S6K Activation for Estrogen Receptor Negative Breast Cancer Prevention. Cancer Prevention Research (Philadelphia, Pa.). PMID 28877935 DOI: 10.1158/1940-6207.Capr-17-0106 |
0.568 |
|
| 2017 |
Joshi S, Yang J, Wang Q, Li P, Wang H, Zhang Q, Xiong Y, Pickering BF, Parker-Thornburg J, Behringer RR, Yu D. 14-3-3ζ loss impedes oncogene-induced mammary tumorigenesis and metastasis by attenuating oncogenic signaling. American Journal of Cancer Research. 7: 1654-1664. PMID 28861322 |
0.71 |
|
| 2017 |
Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, Clifton GT, Sukhumalchandra P, Ma Q, Reddy SM, Yu D, Molldrem JJ, Peoples GE, Alatrash G, Mittendorf EA. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Research. PMID 28819024 DOI: 10.1158/0008-5472.Can-16-2774 |
0.379 |
|
| 2017 |
Zhang C, Lowery FJ, Yu D. Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis. Journal of Visualized Experiments : Jove. PMID 28287553 DOI: 10.3791/55085 |
0.385 |
|
| 2017 |
Zhou Z, Li M, Zhang L, Yu D. Abstract 3923: Oncogenic kinase-induced PKM2 Y105 phosphorylation promotes tumorigenesis and cancer stem cell-like property Cancer Research. 77: 3923-3923. DOI: 10.1158/1538-7445.Am2017-3923 |
0.546 |
|
| 2016 |
Zhang C, Yu D. Advances in decoding breast cancer brain metastasis. Cancer Metastasis Reviews. PMID 27873078 DOI: 10.1007/S10555-016-9638-9 |
0.334 |
|
| 2016 |
Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, ... ... Yu D, et al. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. PMID 27866850 DOI: 10.1016/J.Ccell.2016.10.010 |
0.524 |
|
| 2016 |
Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, ... ... Yu D, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature Communications. 7: 12632. PMID 27572267 DOI: 10.1038/Ncomms12632 |
0.456 |
|
| 2016 |
Acharya S, Xu J, Wang X, Jain S, Wang H, Zhang Q, Chang CC, Bower J, Arun B, Seewaldt V, Yu D. Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. American Journal of Cancer Research. 6: 981-95. PMID 27293993 |
0.438 |
|
| 2016 |
Chang CC, Zhang C, Zhang Q, Sahin O, Wang H, Xu J, Xiao Y, Zhang J, Rehman SK, Li P, Hung MC, Behbod F, Yu D. Upregulation of lactate dehydrogenase a by 14-3-3ζ leads to increased glycolysis critical for breast cancer initiation and progression. Oncotarget. PMID 27150057 DOI: 10.18632/Oncotarget.9136 |
0.677 |
|
| 2016 |
Lowery FJ, Acharya S, Xia Y, Zhang C, Saunus JM, Yu D. Abstract LB-350: In vivo kinome screen reveals potential drivers of brain metastasis Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-350 |
0.432 |
|
| 2016 |
Chang C, Zhang C, Sahin O, Zhang Q, Wang H, Zhang J, Rehman S, Li P, Yu D. Abstract LB-313: Upregulation of lactate dehydrogenase A by 14-3-3ζ leads to increased glycolysis critical for breast cancer initiation and progression Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-313 |
0.51 |
|
| 2016 |
Zhang L, Zhang S, Yao J, Lowery FJL, Zhang Q, Huang W, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty J, Palmieri D, ... ... Yu D, et al. Abstract 907: Brain microenvironment induced PTEN loss by microRNAs promotes brain metastasis Cancer Research. 76: 907-907. DOI: 10.1158/1538-7445.Am2016-907 |
0.4 |
|
| 2016 |
Acharya S, Xu J, Wang X, Jain S, Wang H, Zhang Q, Bower J, Richards-Kortum R, Yu D. Abstract 832: Preventing the progression of estrogen receptor-negative/HER2-overexpressing early stage breast disease by lapatinib Cancer Research. 76: 832-832. DOI: 10.1158/1538-7445.Am2016-832 |
0.515 |
|
| 2016 |
Yuan X, Xiao Y, Kuo W, Yu D. Abstract 4977: Immunogenic chemotherapy synergize PD-1 blockade by enhancing dendritic cells infiltration in triple-negative breast cancer (TNBC) Cancer Research. 76: 4977-4977. DOI: 10.1158/1538-7445.Am2016-4977 |
0.472 |
|
| 2015 |
Rahal OM, Nie L, Chan LC, Li CW, Hsu YH, Hsu J, Yu D, Hung MC. Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells. American Journal of Cancer Research. 5: 3624-34. PMID 26885451 |
0.538 |
|
| 2015 |
Bowie M, Pilie P, Wulfkuhle J, Lem S, Hoffman A, Desai S, Petricoin E, Carter A, Ambrose A, Seewaldt V, Yu D, Ibarra Drendall C. Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. World Journal of Clinical Oncology. 6: 299-311. PMID 26677444 DOI: 10.5306/Wjco.V6.I6.299 |
0.494 |
|
| 2015 |
Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty JH, Palmieri D, ... ... Yu D, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. PMID 26479035 DOI: 10.1038/Nature15376 |
0.563 |
|
| 2015 |
Jain S, Wang X, Chang CC, Ibarra-Drendall C, Wang H, Zhang Q, Brady SW, Li P, Zhao H, Dobbs J, Kyrish M, Tkaczyk TS, Ambrose A, Sistrunk C, Arun B, ... ... Yu D, et al. Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. Cancer Research. PMID 26383165 DOI: 10.1158/0008-5472.Can-14-2345 |
0.553 |
|
| 2015 |
Kanojia D, Balyasnikova IV, Morshed RA, Frank RT, Yu D, Zhang L, Spencer DA, Kim JW, Han Y, Yu D, Ahmed AU, Aboody KS, Lesniak MS. Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases. Stem Cells (Dayton, Ohio). PMID 26260958 DOI: 10.1002/Stem.2109 |
0.422 |
|
| 2015 |
Brady SW, Zhang J, Tsai MH, Yu D. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. Cancer Biology & Therapy. 16: 402-11. PMID 25692408 DOI: 10.1080/15384047.2014.1002693 |
0.56 |
|
| 2015 |
Xu J, Acharya S, Sahin O, Zhang Q, Saito Y, Yao J, Wang H, Li P, Zhang L, Lowery FJ, Kuo WL, Xiao Y, Ensor J, Sahin AA, Zhang XH, ... ... Yu D, et al. 14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Cell. 27: 177-92. PMID 25670079 DOI: 10.1016/J.Ccell.2014.11.025 |
0.549 |
|
| 2015 |
Momeny M, Saunus JM, Marturana F, McCart Reed AE, Black D, Sala G, Iacobelli S, Holland JD, Yu D, Da Silva L, Simpson PT, Khanna KK, Chenevix-Trench G, Lakhani SR. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget. 6: 3932-46. PMID 25668816 DOI: 10.18632/Oncotarget.2846 |
0.521 |
|
| 2015 |
Boulbes DR, Arold ST, Chauhan GB, Blachno KV, Deng N, Chang WC, Jin Q, Huang TH, Hsu JM, Brady SW, Bartholomeusz C, Ladbury JE, Stone S, Yu D, Hung MC, et al. HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Molecular Oncology. 9: 586-600. PMID 25435280 DOI: 10.1016/J.Molonc.2014.10.011 |
0.616 |
|
| 2015 |
Xu J, Acharya S, Sahin O, Zhang L, Lowery FJ, Sahin AA, Zhang XH-, Hung M, Yu D. Abstract LB-202: 14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2 Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-202 |
0.591 |
|
| 2015 |
Joshi S, Yang J, Wang Q, Li P, Wang H, Pickering B, Xiong Y, Parker-Thornburg J, Behringer R, Yu D. Abstract 2310: Loss of 14-3-3zeta attenuates miR-126 expression and results in neonatal lethality Cancer Research. 75: 2310-2310. DOI: 10.1158/1538-7445.Am2015-2310 |
0.394 |
|
| 2014 |
Khotskaya YB, Goverdhan A, Shen J, Ponz-Sarvise M, Chang SS, Hsu MC, Wei Y, Xia W, Yu D, Hung MC. S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. American Journal of Translational Research. 6: 361-76. PMID 25075253 |
0.636 |
|
| 2014 |
Thirumurthi U, Shen J, Xia W, LaBaff AM, Wei Y, Li CW, Chang WC, Chen CH, Lin HK, Yu D, Hung MC. MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Science Signaling. 7: ra71. PMID 25074979 DOI: 10.1126/Scisignal.2005076 |
0.702 |
|
| 2014 |
Chang Z, Ju H, Ling J, Zhuang Z, Li Z, Wang H, Fleming JB, Freeman JW, Yu D, Huang P, Chiao PJ. Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis. Plos One. 9: e101452. PMID 25029561 DOI: 10.1371/Journal.Pone.0101452 |
0.347 |
|
| 2014 |
Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, ... ... Yu D, et al. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Research. 74: 4822-35. PMID 24970481 DOI: 10.1158/0008-5472.Can-14-0584 |
0.654 |
|
| 2014 |
Sahin O, Wang Q, Brady SW, Ellis K, Wang H, Chang CC, Zhang Q, Priya P, Zhu R, Wong ST, Landis MD, Muller WJ, Esteva FJ, Chang J, Yu D. Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Research. 24: 542-59. PMID 24675532 DOI: 10.1038/Cr.2014.37 |
0.7 |
|
| 2014 |
Brady SW, Zhang J, Seok D, Wang H, Yu D. Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor. Molecular Cancer Therapeutics. 13: 60-70. PMID 24249715 DOI: 10.1158/1535-7163.Mct-13-0518 |
0.537 |
|
| 2014 |
Rehman SK, Li SH, Wyszomierski SL, Wang Q, Li P, Sahin O, Xiao Y, Zhang S, Xiong Y, Yang J, Wang H, Guo H, Zhang JD, Medina D, Muller WJ, ... Yu D, et al. 14-3-3ζ orchestrates mammary tumor onset and progression via miR-221-mediated cell proliferation. Cancer Research. 74: 363-73. PMID 24197133 DOI: 10.1158/0008-5472.Can-13-2016 |
0.747 |
|
| 2014 |
Khotskaya YB, Goverdhan A, Shen J, Sarvice MP, Chang S, Hsu M, Wei Y, Xia W, Steeg P, Yu D, Hung M. Abstract A49: S6K1 promotes invasiveness of breast cancer cells in a novel model of triple-negative breast cancer metastasis Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Modorg-A49 |
0.669 |
|
| 2014 |
Brady SW, Zhang J, Tsai MH, Yu D. Abstract LB-221: PI3K-independent, Rheb-mediated mTOR activation promotes lapatinib resistance Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-221 |
0.533 |
|
| 2014 |
Xu J, Jain S, Yu D. Abstract 2137: Prevention of HER2 overexpressing early stage breast disease progression by lapatinib Cancer Research. 74: 2137-2137. DOI: 10.1158/1538-7445.Am2014-2137 |
0.534 |
|
| 2014 |
Acharya S, Zhang C, Lowery FL, Zhang Q, Yu D. Abstract 2010: SPHK1 promotes lung metastasis of breast cancer Cancer Research. 74: 2010-2010. DOI: 10.1158/1538-7445.Am2014-2010 |
0.57 |
|
| 2014 |
Sahin O, Wang Q, Brady S, Wang H, Chang C, Wong S, Muller W, Esteva F, Chang J, Yu D. 237: Sequential application of targeted therapies guided by biomarkers overcomes therapy resistance in rapidly evolving highly aggressive mammary tumors European Journal of Cancer. 50: S55. DOI: 10.1016/S0959-8049(14)50208-0 |
0.561 |
|
| 2013 |
Saldana SM, Lee HH, Lowery FJ, Khotskaya YB, Xia W, Zhang C, Chang SS, Chou CK, Steeg PS, Yu D, Hung MC. Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. Plos One. 8: e73406. PMID 24039934 DOI: 10.1371/Journal.Pone.0073406 |
0.701 |
|
| 2013 |
Zhang S, Huang WC, Zhang L, Zhang C, Lowery FJ, Ding Z, Guo H, Wang H, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Research. 73: 5764-74. PMID 23913825 DOI: 10.1158/0008-5472.Can-12-1803 |
0.644 |
|
| 2013 |
Ke S, Wang W, Qiu X, Zhang F, Yustein JT, Cameron AG, Zhang S, Yu D, Zou C, Gao X, Lin J, Yallampalli S, Li M. Multiple target-specific molecular agents for detection and image analysis of breast cancer characteristics in mice. Current Molecular Medicine. 13: 446-58. PMID 23331017 DOI: 10.2174/1566524011313030014 |
0.57 |
|
| 2013 |
Brady S, Zhang J, Yu D. Abstract LB-216: Acquired lapatinib resistance in HER2-positive breast cancer cells is associated with up-regulation of mutant PI3K and/or secondary PI3K mutation. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-216 |
0.509 |
|
| 2013 |
Wang Q, Li S, Wang H, Xiao Y, Sahin O, Brady SW, Li P, Jaffee EM, Hortobagyi GN, Yu D. Abstract LB-215: Concomitant targeting of tumor cells and induction of T cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-215 |
0.5 |
|
| 2013 |
Chang C, Xu J, Wang H, Zhang C, Zhang J, Rehman SK, Li P, Yu D. Abstract 5427: Increased glycolysis by 14-3-3ζ-mediated LDHA up-regulation contributes to transformation of early mammary epithelial cells. Cancer Research. 73: 5427-5427. DOI: 10.1158/1538-7445.Am2013-5427 |
0.498 |
|
| 2013 |
Joshi S, Yang J, Wang Q, Li P, Wang H, Pickering B, Xiong Y, Parker-Thornburg J, Behringer R, Yu D. Abstract 2328: Loss of 14-3-3zeta impairs oncogene-induced mammary tumorigenesis and metastasis. Cancer Research. 73: 2328-2328. DOI: 10.1158/1538-7445.Am2013-2328 |
0.528 |
|
| 2012 |
Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KKC, Flores LG, Shao Y, Hazle JD, Yu D, Wei W, Sarbassov D, Hung MC, et al. The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis. Cell. 151: 913-914. PMID 30360292 DOI: 10.1016/J.Cell.2012.10.025 |
0.468 |
|
| 2012 |
Wang Q, Li SH, Wang H, Xiao Y, Sahin O, Brady SW, Li P, Ge H, Jaffee EM, Muller WJ, Hortobagyi GN, Yu D. Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Research. 72: 4417-28. PMID 22773664 DOI: 10.1158/0008-5472.Can-12-1339-T |
0.714 |
|
| 2012 |
Lowery FJ, Yu D. Growth factor signaling in metastasis: current understanding and future opportunities. Cancer Metastasis Reviews. 31: 479-91. PMID 22706845 DOI: 10.1007/S10555-012-9380-X |
0.445 |
|
| 2012 |
Tan M, Yu D, Jin Y, Dou L, Li B, Wang Y, Yue J, Liang L. An information transmission model for transcription factor binding at regulatory DNA sites. Theoretical Biology & Medical Modelling. 9: 19. PMID 22672438 DOI: 10.1186/1742-4682-9-19 |
0.309 |
|
| 2012 |
Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, Hazle JD, Yu D, Wei W, Sarbassov D, Hung MC, et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 149: 1098-111. PMID 22632973 DOI: 10.1016/J.Cell.2012.02.065 |
0.648 |
|
| 2012 |
Kumar A, Xu J, Sung B, Kumar S, Yu D, Aggarwal BB, Mehta K. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Research : Bcr. 14: R4. PMID 22225906 DOI: 10.1186/Bcr3085 |
0.361 |
|
| 2012 |
Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends in Pharmacological Sciences. 33: 122-8. PMID 22153719 DOI: 10.1016/J.Tips.2011.11.002 |
0.613 |
|
| 2012 |
Neal CL, Xu J, Li P, Mori S, Yang J, Neal NN, Zhou X, Wyszomierski SL, Yu D. Overexpression of 14-3-3ζ in cancer cells activates PI3K via binding the p85 regulatory subunit. Oncogene. 31: 897-906. PMID 21743495 DOI: 10.1038/Onc.2011.284 |
0.564 |
|
| 2012 |
Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF, Wulfkuhle J, Liotta LA, Lem S, Baker JC, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, ... ... Yu D, et al. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Research and Treatment. 132: 487-98. PMID 21647677 DOI: 10.1007/S10549-011-1609-9 |
0.483 |
|
| 2012 |
Yu D. The role of oncogenes in drug resistance. Cytotechnology. 27: 283-92. PMID 19002799 DOI: 10.1023/A:1008053913764 |
0.34 |
|
| 2012 |
Xu J, Neal CL, Li P, Mori S, Yang J, Neal NN, Zhou X, Wyszomierski SL, Yu D. Abstract 987: Overexpression of 14-3-3α in cancer cells activates PI3K via binding the p85 regulatory subunit Cancer Research. 72: 987-987. DOI: 10.1158/1538-7445.Am2012-987 |
0.504 |
|
| 2012 |
Khotskaya YB, Shen J, Chang S, Yu D, Steeg PS, Hung M. Abstract 3290: A novel model of breast cancer metastasis: Killing two birds with one stone Cancer Research. 72: 3290-3290. DOI: 10.1158/1538-7445.Am2012-3290 |
0.587 |
|
| 2012 |
Zhao Y, Zhou M, LeDoux S, Wilson G, Yu D, Price J, Fodstad O, Tan M. Abstract 3208: Overcoming cancer therapeutic resistance by targeting dysregulated glucose metabolism Cancer Research. 72: 3208-3208. DOI: 10.1158/1538-7445.Am2012-3208 |
0.654 |
|
| 2012 |
Zhang S, Zhang C, Huang W, Lowery FJ, Huang S, Aldape KD, Steeg PS, Yu D. Abstract 2974: Combating breast cancer brain metastasis by targeting Src family kinases Cancer Research. 72: 2974-2974. DOI: 10.1158/1538-7445.Am2012-2974 |
0.633 |
|
| 2012 |
Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF, Wulfkuhle J, Liotta LA, Lem S, Baker JC, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, ... ... Yu D, et al. Erratum: Pilot and feasibility study: Prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways (Breast Cancer Research and Treatment (2012) 132 (487-498) DOI: 10.1007/s10549-011-1609-9) Breast Cancer Research and Treatment. 135. DOI: 10.1007/S10549-012-2227-X |
0.458 |
|
| 2011 |
Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell. 20: 341-56. PMID 21907925 DOI: 10.1016/J.Ccr.2011.07.017 |
0.785 |
|
| 2011 |
Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, ... Yu D, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3126-32. PMID 21730275 DOI: 10.1200/Jco.2010.32.2321 |
0.679 |
|
| 2011 |
Zhang C, Yu D. Microenvironment determinants of brain metastasis. Cell & Bioscience. 1: 8. PMID 21711688 DOI: 10.1186/2045-3701-1-8 |
0.351 |
|
| 2011 |
Kumar A, Gao H, Xu J, Reuben J, Yu D, Mehta K. Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. Plos One. 6: e20701. PMID 21687668 DOI: 10.1371/Journal.Pone.0020701 |
0.392 |
|
| 2011 |
Baker EL, Srivastava J, Yu D, Bonnecaze RT, Zaman MH. Cancer cell migration: integrated roles of matrix mechanics and transforming potential. Plos One. 6: e20355. PMID 21647371 DOI: 10.1371/Journal.Pone.0020355 |
0.326 |
|
| 2011 |
Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, Sahin AA, Esteva FJ, Hortobagyi GN, Yu D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Medicine. 17: 461-9. PMID 21399647 DOI: 10.1038/Nm.2309 |
0.609 |
|
| 2011 |
Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, Liu M, Chen CT, Yu D, Hung MC. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nature Cell Biology. 13: 317-23. PMID 21336307 DOI: 10.1038/Ncb2173 |
0.789 |
|
| 2011 |
Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF, Wulfkuhle JD, Liotta LA, Lem S, Baker JC, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, ... ... Yu D, et al. Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 476-82. PMID 21242333 DOI: 10.1158/1055-9965.Epi-10-0847 |
0.427 |
|
| 2011 |
Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Research. 71: 603-13. PMID 21123450 DOI: 10.1158/0008-5472.Can-10-3185 |
0.663 |
|
| 2011 |
Zhang S, Huang W, Li P, Guo H, Poh S, Brady S, Xiong Y, Tseng L, Li S, Ding Z, Sahin A, Esteva F, Hortobagyi G, Yu D. Abstract LB-379: Combating trastuzumab resistance by targeting Src, a common node downstream of multiple resistance pathways Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-379 |
0.5 |
|
| 2011 |
Li S, Wyszomierski SL, Li P, Wang Q, Rehman SK, Xiong Y, Yang J, Guo H, Zhang S, Fang D, Medina D, Muller WJ, Yu D. Abstract 2386: Overexpression of 14-3-3ζ in mouse mammary gland promotes mammary tumor development and progression by enhancing multiple tumor-associated properties Cancer Research. 71: 2386-2386. DOI: 10.1158/1538-7445.Am2011-2386 |
0.62 |
|
| 2011 |
Boulbes, Jin Q, Arold S, Ladbury J, Yu D, Esteva F. S2-7: Mechanisms of Action and Biological Significance of HER2 Mutations in HER2−Overexpressing Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-S2-7 |
0.479 |
|
| 2011 |
Chang C, Chao C, Xia W, Yang J, Xiong Y, Li C, Yu W, Rehman SK, Hsu JL, Lee H, Liu M, Chen C, Yu D, Hung M. Erratum: p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs Nature Cell Biology. 13: 1466-1466. DOI: 10.1038/Ncb2401 |
0.647 |
|
| 2010 |
Neal CL, Yu D. 14-3-3ζ as a prognostic marker and therapeutic target for cancer. Expert Opinion On Therapeutic Targets. 14: 1343-54. PMID 21058923 DOI: 10.1517/14728222.2010.531011 |
0.44 |
|
| 2010 |
Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/J.Bbrc.2010.10.126 |
0.809 |
|
| 2010 |
Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. Plos One. 5: e13390. PMID 20967228 DOI: 10.1371/Journal.Pone.0013390 |
0.322 |
|
| 2010 |
Baker EL, Lu J, Yu D, Bonnecaze RT, Zaman MH. Cancer cell stiffness: integrated roles of three-dimensional matrix stiffness and transforming potential. Biophysical Journal. 99: 2048-57. PMID 20923638 DOI: 10.1016/J.Bpj.2010.07.051 |
0.355 |
|
| 2010 |
Cheng X, Xia W, Yang JY, Hsu JL, Lang JY, Chou CK, Du Y, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. Cancer Research. 70: 7684-9. PMID 20841468 DOI: 10.1158/0008-5472.Can-09-3231 |
0.816 |
|
| 2010 |
Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. The American Journal of Pathology. 177: 1647-56. PMID 20813970 DOI: 10.2353/Ajpath.2010.090885 |
0.647 |
|
| 2010 |
Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4325-30. PMID 20622047 DOI: 10.1158/1078-0432.Ccr-09-2990 |
0.644 |
|
| 2010 |
Lu J, Yu D. Invasive breast cancer development: "fatal accident" from malfunctions in both "motor" and "brake". Cell Cycle (Georgetown, Tex.). 9: 421-2. PMID 20090417 DOI: 10.4161/cc.9.3.10633 |
0.328 |
|
| 2010 |
Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nature Reviews. Clinical Oncology. 7: 98-107. PMID 20027191 DOI: 10.1038/Nrclinonc.2009.216 |
0.607 |
|
| 2010 |
Morrow PH, Wulf GM, Booser DJ, Moore JA, Flores PR, Krop IE, Winer EP, Hortobagyi GN, Yu D, Esteva FJ. Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer. Journal of Clinical Oncology. 28: 1014-1014. DOI: 10.1200/Jco.2010.28.15_Suppl.1014 |
0.382 |
|
| 2010 |
Lu J, Li P, Yu D. Abstract 5760: 14-3-3zeta cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition Cancer Research. 70: 5760-5760. DOI: 10.1158/1538-7445.Am10-5760 |
0.554 |
|
| 2010 |
Wang W, Qiu X, Carmeron AG, Zhang S, Yu D, Mawad ME, Shi K. Abstract 5233: Imaging breast cancer xenograft using multienergy modality and target-specific molecular agents Cancer Research. 70: 5233-5233. DOI: 10.1158/1538-7445.Am10-5233 |
0.543 |
|
| 2010 |
Xu J, Yu D. Abstract 4928: 14-3-3ζ-mediated hypomethylation of c-myc oncogene by downregulation of Dnmts contributes to initiation and progression of breast cancer Cancer Research. 70: 4928-4928. DOI: 10.1158/1538-7445.Am10-4928 |
0.518 |
|
| 2010 |
Rehman SK, Huang W, Yu D. Abstract 4033: MiR-21 upregulation in breast cancer cells leads to PTEN loss and Herceptin resistance Cancer Research. 70: 4033-4033. DOI: 10.1158/1538-7445.Am10-4033 |
0.401 |
|
| 2010 |
Yang J, Li P, Yu D. Abstract 3283: Developmental and metabolic deregulation in 14-3-3zeta knockout mouse Cancer Research. 70: 3283-3283. DOI: 10.1158/1538-7445.Am10-3283 |
0.453 |
|
| 2010 |
Li S, Hawthorne VS, Neal CL, Sanghera S, Xu J, Yang J, Guo H, Steeg PS, Yu D. Abstract 262: Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through NF-κB activation Cancer Research. 70: 262-262. DOI: 10.1158/1538-7445.Am10-262 |
0.849 |
|
| 2009 |
Li SH, Hawthorne VS, Neal CL, Sanghera S, Xu J, Yang J, Guo H, Steeg PS, Yu D. Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation. Cancer Research. 69: 9163-8. PMID 19951994 DOI: 10.1158/0008-5472.Can-09-2483 |
0.85 |
|
| 2009 |
Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, Feng X, Seewaldt VL, Muller WJ, Sahin A, Hung MC, ... Yu D, et al. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell. 16: 195-207. PMID 19732720 DOI: 10.1016/J.Ccr.2009.08.010 |
0.679 |
|
| 2009 |
Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, Tan M. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene. 28: 3689-701. PMID 19668225 DOI: 10.1038/Onc.2009.229 |
0.655 |
|
| 2009 |
Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, Hortobagyi GN, Yu D. Breast cancer metastasis: challenges and opportunities. Cancer Research. 69: 4951-3. PMID 19470768 DOI: 10.1158/0008-5472.Can-09-0099 |
0.492 |
|
| 2009 |
Liao Y, Wei Y, Zhou X, Yang JY, Dai C, Chen YJ, Agarwal NK, Sarbassov D, Shi D, Yu D, Hung MC. Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation. Oncogene. 28: 2436-45. PMID 19448664 DOI: 10.1038/Onc.2009.98 |
0.785 |
|
| 2009 |
Hawthorne VS, Huang WC, Neal CL, Tseng LM, Hung MC, Yu D. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Molecular Cancer Research : McR. 7: 592-600. PMID 19372587 DOI: 10.1158/1541-7786.Mcr-08-0316 |
0.852 |
|
| 2009 |
Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensor J, Hittelman W, Hung MC, Yu D. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Research. 69: 3425-32. PMID 19318578 DOI: 10.1158/0008-5472.Can-08-2765 |
0.848 |
|
| 2009 |
Hung MC, Mills GB, Yu D. Oxygen sensor boosts growth factor signaling. Nature Medicine. 15: 246-7. PMID 19265822 DOI: 10.1038/Nm0309-246 |
0.469 |
|
| 2009 |
Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, Symmans F, Yu D. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1326-34. PMID 19228734 DOI: 10.1158/1078-0432.Ccr-08-0954 |
0.644 |
|
| 2008 |
Danes CG, Wyszomierski SL, Lu J, Neal CL, Yang W, Yu D. 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Research. 68: 1760-7. PMID 18339856 DOI: 10.1158/0008-5472.Can-07-3177 |
0.854 |
|
| 2008 |
Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, ... ... Yu D, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nature Cell Biology. 10: 138-48. PMID 18204439 DOI: 10.1038/Ncb1676 |
0.785 |
|
| 2008 |
Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Molecular Carcinogenesis. 47: 701-6. PMID 18176935 DOI: 10.1002/Mc.20413 |
0.608 |
|
| 2007 |
Liao Y, Yu D, Hung MC. Novel approaches for chemosensitization of breast cancer cells: the E1A story. Advances in Experimental Medicine and Biology. 608: 144-69. PMID 17993239 DOI: 10.1007/978-0-387-74039-3_11 |
0.666 |
|
| 2007 |
Tan M, Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Advances in Experimental Medicine and Biology. 608: 119-29. PMID 17993237 DOI: 10.1007/978-0-387-74039-3_9 |
0.493 |
|
| 2007 |
Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, Mills GB, Hortobagyi GN, Esteva FJ, Yu D. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5883-8. PMID 17908983 DOI: 10.1158/1078-0432.Ccr-06-2837 |
0.754 |
|
| 2007 |
Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, Pisters PW, Lazar AJ, Yu D, Pollock RE, Lev D. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Molecular Cancer Therapeutics. 6: 1650-60. PMID 17513613 DOI: 10.1158/1535-7163.Mct-06-0636 |
0.391 |
|
| 2006 |
Liu J, Zhan M, Hannay JA, Das P, Bolshakov SV, Kotilingam D, Yu D, Lazar AF, Pollock RE, Lev D. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Molecular Cancer Research : McR. 4: 803-10. PMID 17077165 DOI: 10.1158/1541-7786.Mcr-06-0201 |
0.361 |
|
| 2006 |
Ping B, He X, Xia W, Lee DF, Wei Y, Yu D, Mills G, Shi D, Hung MC. Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers. International Journal of Oncology. 29: 1103-10. PMID 17016640 |
0.818 |
|
| 2006 |
Zhang L, Hannay JA, Liu J, Das P, Zhan M, Nguyen T, Hicklin DJ, Yu D, Pollock RE, Lev D. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Research. 66: 8770-8. PMID 16951193 DOI: 10.1158/0008-5472.Can-06-1217 |
0.347 |
|
| 2006 |
Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice. Oncology. 3: 269-80. PMID 16683005 DOI: 10.1038/Ncponc0509 |
0.634 |
|
| 2006 |
Tan M, Lan KH, Yao J, Lu CH, Sun M, Neal CL, Lu J, Yu D. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Research. 66: 3764-72. PMID 16585203 DOI: 10.1158/0008-5472.Can-05-2747 |
0.806 |
|
| 2006 |
Konopleva M, Zhang W, Shi YX, McQueen T, Tsao T, Abdelrahim M, Munsell MF, Johansen M, Yu D, Madden T, Safe SH, Hung MC, Andreeff M. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Molecular Cancer Therapeutics. 5: 317-28. PMID 16505105 DOI: 10.1158/1535-7163.Mct-05-0350 |
0.634 |
|
| 2006 |
Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN, Yu D. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Research. 66: 2028-37. PMID 16489002 DOI: 10.1158/0008-5472.Can-04-4559 |
0.841 |
|
| 2006 |
Tan M, Li P, Sun M, Yin G, Yu D. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene. 25: 3286-95. PMID 16407820 DOI: 10.1038/Sj.Onc.1209361 |
0.655 |
|
| 2006 |
Efferson CL, Tsuda N, Kawano K, Nistal-Villán E, Sellappan S, Yu D, Murray JL, García-Sastre A, Ioannides CG. Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells. Journal of Virology. 80: 383-94. PMID 16352563 DOI: 10.1128/JVI.80.1.383-394.2006 |
0.798 |
|
| 2006 |
Ping B, He X, Xia W, Lee DF, Wei Y, Yu D, Mills G, Shi D, Hung MC. Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKβ overexpression in human breast cancers International Journal of Oncology. 29: 1103-1110. DOI: 10.3892/Ijo.29.5.1103 |
0.512 |
|
| 2006 |
Neal CL, Yu D. Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer Breast Diseases. 16: 374-375. DOI: 10.1016/S1043-321X(05)80306-6 |
0.359 |
|
| 2006 |
Hannay JAF, Yu D. Mechanisms of breast cancer resistance to chemotherapy Breast Cancer and Molecular Medicine. 783-803. DOI: 10.1007/978-3-540-28266-2_36 |
0.383 |
|
| 2005 |
Lan KH, Lu CH, Yu D. Mechanisms of trastuzumab resistance and their clinical implications. Annals of the New York Academy of Sciences. 1059: 70-5. PMID 16382045 DOI: 10.1196/Annals.1339.026 |
0.751 |
|
| 2005 |
Wyszomierski SL, Yu D. A knotty turnabout?: Akt1 as a metastasis suppressor. Cancer Cell. 8: 437-9. PMID 16338656 DOI: 10.1016/J.Ccr.2005.11.006 |
0.462 |
|
| 2005 |
Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang D, Jing T, Yu D. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Research. 65: 1858-67. PMID 15753384 DOI: 10.1158/0008-5472.Can-04-2353 |
0.836 |
|
| 2005 |
Zhan M, Yu D, Liu J, Glazer RI, Hannay J, Pollock RE. Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. The Journal of Biological Chemistry. 280: 4825-33. PMID 15563462 DOI: 10.1074/Jbc.M407450200 |
0.463 |
|
| 2005 |
Tan M, Sun M, Yu D. 1–22 The Role of PTEN and Its Signalling Pathways, Including AKT, in Breast Cancer; An Assessment of Relationships With Other Prognostic Factors and With Outcome Breast Diseases: a Year Book Quarterly. 16: 53-54. DOI: 10.1016/S1043-321X(05)80037-2 |
0.359 |
|
| 2004 |
Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 6: 459-69. PMID 15542430 DOI: 10.1016/J.Ccr.2004.09.027 |
0.811 |
|
| 2004 |
Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6779-88. PMID 15501954 DOI: 10.1158/1078-0432.Ccr-04-0112 |
0.851 |
|
| 2004 |
Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 6: 117-27. PMID 15324695 DOI: 10.1016/J.Ccr.2004.06.022 |
0.835 |
|
| 2004 |
Hawthorne VS, Yu D. PI3K: Missense Mutation Motivates Malignancy. Cancer Biology & Therapy. 3: 776-7. PMID 15280668 DOI: 10.4161/Cbt.3.8.1031 |
0.787 |
|
| 2004 |
Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu D. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Research. 64: 3479-85. PMID 15150101 DOI: 10.1158/0008-5472.Can-3299-2 |
0.822 |
|
| 2004 |
Klos KS, Yu D. Liposomal mediated transfer of ErbB2 antisense DNA: coming of age in the war against cancer. Cancer Biology & Therapy. 3: 205-6. PMID 14764991 DOI: 10.4161/Cbt.3.2.714 |
0.793 |
|
| 2004 |
Efferson C, Kawano K, Sellappan S, Yu D, Babaian R, Palese P, Garcia-Sastre A, Ioannides C, Murray J. Prostate Tumor Cells Infected with a Recombinant Influenza Virus with Truncated NS1 Gene NS1 (1-126) Activate Cytolytic CD8+ Cells Which Recognize Non-Infected Tumors Journal of Immunotherapy. 27: S53. DOI: 10.1097/00002371-200411000-00190 |
0.773 |
|
| 2003 |
Hannay JA, Yu D. Silibinin: a thorny therapeutic for EGF-R expressing tumors? Cancer Biology & Therapy. 2: 532-3. PMID 14614321 DOI: 10.4161/Cbt.2.5.536 |
0.35 |
|
| 2003 |
Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer. 98: 1377-85. PMID 14508823 DOI: 10.1002/cncr.11656 |
0.784 |
|
| 2003 |
Yang W, Klos KS, Zhou X, Yao J, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. Cancer. 98: 1123-30. PMID 12973835 DOI: 10.1002/Cncr.11625 |
0.828 |
|
| 2002 |
Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Research. 62: 5703-10. PMID 12384528 |
0.838 |
|
| 2002 |
Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer. 94: 2855-61. PMID 12115372 DOI: 10.1002/cncr.10553 |
0.769 |
|
| 2002 |
Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC, Yu D. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Molecular Cell. 9: 993-1004. PMID 12049736 DOI: 10.1016/S1097-2765(02)00510-5 |
0.823 |
|
| 2002 |
Bourguignon L, Lan K, Singleton P, Lin S, Yu D, Hung M. Localizing the EGF receptor - Reply Nature Cell Biology. 4: E22-E23. DOI: 10.1038/Ncb0202-E22B |
0.696 |
|
| 2001 |
Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, Yu D. Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene. 20: 8066-74. PMID 11781819 DOI: 10.1038/Sj.Onc.1204944 |
0.801 |
|
| 2001 |
Zhan M, Yu D, Lang A, Li L, Pollock RE. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Cancer. 92: 1556-66. PMID 11745235 DOI: 10.1002/1097-0142(20010915)92:6<1556::Aid-Cncr1482>3.0.Co;2-S |
0.331 |
|
| 2001 |
Makino K, Yu D, Hung MC. Transcriptional upregulation and activation of p55Cdc via p34(cdc2) in Taxol-induced apoptosis. Oncogene. 20: 2537-43. PMID 11420663 DOI: 10.1038/sj.onc.1204366 |
0.365 |
|
| 2001 |
Xiong S, Grijalva R, Zhang L, Nguyen NT, Pisters PW, Pollock RE, Yu D. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Research. 61: 1727-32. PMID 11245489 |
0.833 |
|
| 2001 |
Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 19: 6115-21. PMID 11156524 DOI: 10.1038/Sj.Onc.1203972 |
0.502 |
|
| 2000 |
Grothey A, Hashizume R, Ji H, Tubb BE, Patrick CW, Yu D, Mooney EE, McCrea PD. C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines Oncogene. 19: 4864-4875. PMID 11039904 DOI: 10.1038/Sj.Onc.1203838 |
0.501 |
|
| 2000 |
Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Bioessays. 22: 673-680. PMID 10878580 DOI: 10.1002/1521-1878(200007)22:7<673::Aid-Bies10>3.0.Co;2-A |
0.531 |
|
| 2000 |
Milas M, Yu D, Lang A, Ge T, Feig B, El-Naggar AK, Pollock RE. Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity. Cancer Gene Therapy. 7: 422-9. PMID 10766348 DOI: 10.1038/Sj.Cgt.7700141 |
0.384 |
|
| 1999 |
Tan M, Grijalva R, Yu D. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Research. 59: 1620-5. PMID 10197638 |
0.835 |
|
| 1999 |
Feig BW, Lu X, Hunt KK, Shan Q, Yu D, Pollock R, Chiao P. Inhibition of the transcription factor nuclear factor-κB by adenoviral-mediated expression of IκBαM results in tumor cell death Surgery. 126: 399-405. DOI: 10.1016/S0039-6060(99)70184-4 |
0.358 |
|
| 1998 |
Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, Hung MC. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Molecular Cell. 2: 581-91. PMID 9844631 DOI: 10.1016/S1097-2765(00)80157-4 |
0.841 |
|
| 1998 |
Yu D, Hung MC. The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. Cancer Metastasis Reviews. 17: 195-202. PMID 9770116 DOI: 10.1023/A:1006054421970 |
0.302 |
|
| 1998 |
Pollock R, Lang A, Ge T, Sun D, Tan M, Yu D. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 4: 1985-94. PMID 9717829 |
0.45 |
|
| 1998 |
Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 16: 2087-94. PMID 9572489 DOI: 10.1038/Sj.Onc.1201729 |
0.835 |
|
| 1998 |
Yao J, Pollock RE, Lang A, Tan M, Pisters PW, Goodrich D, El-Naggar A, Yu D. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 4: 1065-70. PMID 9563903 |
0.478 |
|
| 1997 |
Singletary SE, Dhingra K, Yu D. New strategies in locally advanced breast cancer Cancer Treatment and Research. 90: 253-271. PMID 9367088 DOI: 10.1007/978-1-4615-6165-1_14 |
0.439 |
|
| 1997 |
Liu B, Sun D, Xia W, Hung MC, Yu D. Cross-reactivity of C219 Anti-p170mdr-1 Antibody With p185c-erbB2 in Breast Cancer Cells: Cautions on Evaluating p170mdr-1 Journal of the National Cancer Institute. 89: 1524-1529. PMID 9337349 DOI: 10.1093/Jnci/89.20.1524 |
0.394 |
|
| 1997 |
Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene. 15: 953-60. PMID 9285690 DOI: 10.1038/Sj.Onc.1201250 |
0.657 |
|
| 1997 |
Chen H, Yu D, Chinnadurai G, Karunagaran D, Hung MC. Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. Oncogene. 14: 1965-71. PMID 9150363 DOI: 10.1038/Sj.Onc.1201030 |
0.393 |
|
| 1997 |
Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Research. 57: 1199-205. PMID 9067293 |
0.595 |
|
| 1996 |
Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 13: 1359-65. PMID 8808711 |
0.567 |
|
| 1995 |
Hung MC, Matin A, Zhang Y, Xing X, Sorgi F, Huang L, Yu D. HER-2/neu-targeting gene therapy--a review. Gene. 159: 65-71. PMID 7607574 DOI: 10.1016/0378-1119(94)00459-6 |
0.459 |
|
| 1995 |
Tsai CM, Yu D, Chang KT, Wu LH, Perng RP, Ibrahim NK, Hung MC. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. Journal of the National Cancer Institute. 87: 682-4. PMID 7538595 DOI: 10.1093/Jnci/87.9.682 |
0.373 |
|
| 1992 |
Shi D, He G, Cao S, Pan W, Zhang H‐, Yu D, Hung M‐. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Molecular Carcinogenesis. 5: 213-218. PMID 1350198 DOI: 10.1002/Mc.2940050308 |
0.419 |
|
| Show low-probability matches. |